Inex Pharmaceuticals named Timothy M. Ruane, president and COO, as its president and CEO.
Nancy Chang, Ph.D., co-founder, president and CEO of Tanox, will assume the role of chairman of the company's board of directors. She replaces Osama Mikhail, Ph.D., who will assume the position of lead director. Succeeding Chang as president and CEO will be Danong Chen, Ph.D., MBA, who currently holds the position of vice president of strategy and corporate development at Tanox. In addition, Edward Hu, MBA, has been promoted to senior vice president and COO.
Idera Pharmaceuticals has named Robert W. Karr, M.D., as president.
Cobalis has hired Thomas Stankovich as its new executive VP, CFO.
Baxter International has appointed Robert H. Armstrong to the newly created position of VP, research and development, medical devices and adjacent disposables.
Depomed announced today that Jeff P. Miller has joined the company as VP, regulatory affairs and quality assurance.
ChondroGene Limited has appointed Dr. Daniel H. Farkas as VP, clinical diagnostics.
Favrille has named David Guy as chief commercial officer.
MedImmune has promoted William C. Bertrand, Jr., J.D., to senior VP, general counsel, secretary and corporate compliance officer; Pamela J. Lupien to senior VP, human resources; Genevieve Losonsky, M.D., to VP, clinical development, infectious disease; and Robert Walker, M.D., to VP, clinical development, inflammatory disease. In addition, MedImmune has recruited Anthony Luttrell as VP, quality; Frank J. Malinoski, M.D., Ph.D., as VP, medical affairs, infectious disease; and John J. Whalen, M.D., as VP, clinical development operations.
Lentigen announced its executive team: Boro Dropulic, CEO; Yung Nien Chang, VP of vector development; Gregory J. Feulner, VP of business development; John Woolford, director, business planning.
Albany Molecular Research named Steven R. Hagen, Ph.D., as senior director of analytical quality services.
Genesis Bioventures and Experigen Management announced that Dr. Ivan Labat has joined GBI's restructuring team.
BioSante has engaged Michael C. Snabes, M.D., Ph.D., as an independent consultant to work with BioSante's current product development team.
DeCODE genetics has named Dr. Linda Buck to its board of directors.
William Hoskins has resigned as a member of the board of directors of Isotechnika.
ActivBiotics has elected Michael E. Hanson as a new director.
Elly Reisman has stepped down from the board of directors of Lorus Therapeutics to pursue other business activities.
InterMune announced that David S. Kabakoff, Ph.D., has been elected to its board of directors.
Human Genome Sciences has elected Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals, to the company's board.